<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="ame212486" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Animal Model Exp Med</journal-id><journal-id journal-id-type="iso-abbrev">Animal Model Exp Med</journal-id><journal-id journal-id-type="pmc-domain-id">3615</journal-id><journal-id journal-id-type="pmc-domain">animalmod</journal-id><journal-id journal-id-type="publisher-id">AME2</journal-id><journal-title-group><journal-title>Animal Models and Experimental Medicine</journal-title></journal-title-group><issn pub-type="ppub">2096-5451</issn><issn pub-type="epub">2576-2095</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12431571</article-id><article-id pub-id-type="pmcid-ver">PMC12431571.1</article-id><article-id pub-id-type="pmcaid">12431571</article-id><article-id pub-id-type="pmcaiid">12431571</article-id><article-id pub-id-type="pmid">39468692</article-id><article-id pub-id-type="doi">10.1002/ame2.12486</article-id><article-id pub-id-type="publisher-id">AME212486</article-id><article-id pub-id-type="other">AMEM-2022-0101.R1</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Regular Article</subject><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></subj-group></article-categories><title-group><article-title>Metabolic alterations in human pulmonary artery smooth muscle cells treated with <styled-content style="fixed-case" toggle="no">PDGF</styled-content>&#8208;<styled-content style="fixed-case" toggle="no">BB</styled-content>
</article-title><alt-title alt-title-type="left-running-head">zhang et&#160;al.</alt-title></title-group><contrib-group><contrib id="ame212486-cr-0001" contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="MJ">Meng&#8208;Jie</given-names></name><xref rid="ame212486-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="ame212486-cr-0002" contrib-type="author"><name name-style="western"><surname>Kou</surname><given-names initials="JJ">Jie&#8208;Jian</given-names></name><xref rid="ame212486-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="ame212486-cr-0003" contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="HD">Hong&#8208;Da</given-names></name><xref rid="ame212486-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="ame212486-cr-0004" contrib-type="author"><name name-style="western"><surname>Xie</surname><given-names initials="XM">Xin&#8208;Mei</given-names></name><xref rid="ame212486-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="ame212486-cr-0005" contrib-type="author"><name name-style="western"><surname>Zhou</surname><given-names initials="YF">Yun&#8208;Feng</given-names></name><xref rid="ame212486-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="ame212486-cr-0006" contrib-type="author"><name name-style="western"><surname>Yuan</surname><given-names initials="P">Ping</given-names></name><xref rid="ame212486-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="ame212486-cr-0007" contrib-type="author"><name name-style="western"><surname>Pang</surname><given-names initials="XB">Xiao&#8208;Bin</given-names></name><xref rid="ame212486-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="ame212486-cr-0008" contrib-type="author" corresp="yes"><name name-style="western"><surname>Zhao</surname><given-names initials="LL">Lu&#8208;Ling</given-names></name><xref rid="ame212486-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>zhaoluling@vip.henu.edu.cn</email></address></contrib><contrib id="ame212486-cr-0009" contrib-type="author" corresp="yes"><name name-style="western"><surname>Qiu</surname><given-names initials="J">Jing</given-names></name><xref rid="ame212486-aff-0005" ref-type="aff">
<sup>5</sup>
</xref><address><email>qqjjiuing@163.com</email></address></contrib><contrib id="ame212486-cr-0010" contrib-type="author" corresp="yes"><name name-style="western"><surname>He</surname><given-names initials="YY">Yang&#8208;Yang</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3517-572X</contrib-id><xref rid="ame212486-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>heyangyang@vip.henu.edu.cn</email></address></contrib></contrib-group><aff id="ame212486-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">School of Pharmacy</named-content>
<institution>Henan University</institution>
<city>Kaifeng</city>
<country country="CN">China</country>
</aff><aff id="ame212486-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Pharmacy</named-content>
<institution>Huaihe Hospital of Henan University</institution>
<city>Kaifeng</city>
<country country="CN">China</country>
</aff><aff id="ame212486-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases</named-content>
<institution>Chinese Academy of Medical Sciences and Peking Union Medical College</institution>
<city>Beijing</city>
<country country="CN">China</country>
</aff><aff id="ame212486-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Cardiopulmonary Circulation, Shanghai Pulmonary Hospital</named-content>
<institution>Tongji University School of Medicine</institution>
<city>Shanghai</city>
<country country="CN">China</country>
</aff><aff id="ame212486-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Cardiology</named-content>
<institution>The First Affiliated Hospital of Zhengzhou University</institution>
<city>Zhengzhou</city>
<country country="CN">China</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Lu&#8208;Ling Zhao and Yang&#8208;Yang He, School of Pharmacy, Henan University, Kaifeng 475&#8201;004, China.<break/>
Email: <email>zhaoluling@vip.henu.edu.cn</email> and <email>heyangyang@vip.henu.edu.cn</email><break/>
Jing Qiu, Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450&#8201;052, China.<break/>
Email: <email>qqjjiuing@163.com</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>28</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>7</month><year>2025</year></pub-date><volume>8</volume><issue seq="110">7</issue><issue-id pub-id-type="pmc-issue-id">496817</issue-id><issue-id pub-id-type="doi">10.1002/ame2.v8.7</issue-id><issue-title content-type="special-issue-title">Themed Issue: Mechanism Verification of Plant Bioactive Components</issue-title><fpage>1268</fpage><lpage>1276</lpage><history><date date-type="received"><day>28</day><month>11</month><year>2022</year></date><date date-type="accepted"><day>07</day><month>8</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>28</day><month>10</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 17:25:36.317"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2024 The Author(s). <italic toggle="yes">Animal Models and Experimental Medicine</italic> published by John Wiley &amp; Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="AME2-8-1268.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:AME2-8-1268.pdf"/><abstract><title>Abstract</title><sec id="ame212486-sec-0001"><title>Background</title><p>Metabolic abnormalities are considered to play a key regulatory role in vascular remodeling of pulmonary arterial hypertension. However, to date, there is a paucity of research documenting the changes in metabolome profiles within the supernatants of pulmonary artery smooth muscle cells (PASMC) during their transition from a contractile to a synthetic phenotype.</p></sec><sec id="ame212486-sec-0002"><title>Methods</title><p>CCK&#8208;8 and Edu staining assays were used to evaluate the cell viability and proliferation of human PASMCs. IncuCyte ZOOM imaging system was used to continuously and automatically detect the migration of the PASMCs. A targeted metabolomics profiling was performed to quantitatively analyze 121 metabolites in the supernatant. Orthogonal partial least squares discriminant analysis was used to discriminate between PDGF&#8208;BB&#8208;induced PASMCs and controls. Metabolite set enrichment analysis was adapted to exploit the most disturbed metabolic pathways.</p></sec><sec id="ame212486-sec-0003"><title>Results</title><p>Human PASMCs exhibited a transformation from contractile phenotype to synthetic phenotype after PDGF&#8208;BB induction, along with a significant increase in cell viability, proliferation, and migration. Metabolites in the supernatants of PASMCs treated with or without PDGF&#8208;BB were well profiled. Eleven metabolites were found to be significantly upregulated, whereas seven metabolites were downregulated in the supernatants of PASMCs induced by PDGF&#8208;BB compared to the vehicle&#8208;treated cells. Fourteen pathways were involved, and pyruvate metabolism pathway was ranked first with the highest enrichment impact followed by glycolysis/gluconeogenesis and pyrimidine metabolism.</p></sec><sec id="ame212486-sec-0004"><title>Conclusions</title><p>Significant and extensive metabolic abnormalities occurred during the phenotypic transformation of PASMCs. Disturbance of pyruvate metabolism pathway might contribute to pulmonary vascular remodeling.</p></sec></abstract><abstract abstract-type="graphical"><p>Metabolic abnormalities are considered to play a key regulatory role in vascular remodeling of pulmonary arterial hypertension. We analyzed the metabolome in the culture supernatants of human pulmonary artery smooth muscle cells (PASMC) during the malignant proliferation phenotype transition via a targeted metabolomics method. Significant and extensive metabolic abnormalities occurred during phenotypic transformation of PASMCs, and disturbance of pyruvate metabolism pathway might contribute to pulmonary vascular remodeling.<boxed-text position="anchor" content-type="graphic" id="ame212486-blkfxd-0001" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="AME2-8-1268-g005.jpg"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="ame212486-kwd-0001">metabolomics</kwd><kwd id="ame212486-kwd-0002">pulmonary artery hypertension</kwd><kwd id="ame212486-kwd-0003">pyruvate metabolism</kwd><kwd id="ame212486-kwd-0004">vascular remodeling</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Joint Fund of Science and Technology R&amp;D Plan of Henan Province</institution></institution-wrap></funding-source><award-id>232103810056</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>Special Project for Key R&amp;D and Promotion of Henan Province</institution></institution-wrap></funding-source><award-id>232102311233</award-id><award-id>242102311034</award-id></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>National Natural Science Foundation of China</institution><institution-id institution-id-type="doi">10.13039/501100001809</institution-id></institution-wrap></funding-source><award-id>82170058</award-id><award-id>82241007</award-id></award-group></funding-group><counts><fig-count count="7"/><table-count count="0"/><page-count count="9"/><word-count count="5200"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>July 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.2 mode:remove_FC converted:12.09.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="AME212486-cit-2001"><string-name name-style="western"><surname>Zhang</surname><given-names>M&#8208;J</given-names></string-name>, <string-name name-style="western"><surname>Kou</surname><given-names>J&#8208;J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>H&#8208;D</given-names></string-name>, et al. <article-title>Metabolic alterations in human pulmonary artery smooth muscle cells treated with <styled-content style="fixed-case" toggle="no">PDGF</styled-content>&#8208;<styled-content style="fixed-case" toggle="no">BB</styled-content>
</article-title>. <source>Anim Models Exp Med</source>. <year>2025</year>;<volume>8</volume>:<fpage>1268</fpage>&#8208;<lpage>1276</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ame2.12486</pub-id><pub-id pub-id-type="pmcid">PMC12431571</pub-id><pub-id pub-id-type="pmid">39468692</pub-id></mixed-citation>
</p><fn-group id="ame212486-ntgp-0001"><fn fn-type="equal" id="ame212486-note-0001"><p>Meng&#8208;Jie Zhang, Jie&#8208;Jian Kou and Hong&#8208;Da Zhang have contributed equally to this study and are co&#8208;first authors.</p></fn></fn-group></notes></front><body id="ame212486-body-0001"><sec id="ame212486-sec-0005"><label>1</label><title>INTRODUCTION</title><p>Pulmonary arterial hypertension (PAH) is a malignant cardiovascular disease that may involve multiple clinical conditions and may be associated with a variety of cardiovascular and respiratory diseases.<xref rid="ame212486-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="ame212486-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> The application of targeted drugs has significantly improved the survival rate of PAH patients in the past 20&#8201;years.<xref rid="ame212486-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> However, the existing targeted therapeutic strategies cannot reverse pulmonary vascular remodeling, and the overall survival of PAH is still not satisfactory.<xref rid="ame212486-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="ame212486-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>
</p><p>The pathological mechanism of PAH is complex, involving genetics, epigenetics, environmental factors, inflammation, and hormones.<xref rid="ame212486-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="ame212486-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="ame212486-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="ame212486-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> The role of metabolic regulation in vascular remodeling of PAH has gained increasing attention, especially with the rapid development of metabolomics technology in recent years. Some potential biomarkers were identified by analyzing the endogenous metabolites in plasma of 71 patients with PAH utilizing a targeted metabolomics assay.<xref rid="ame212486-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Transcriptomics and metabolomics were combined to reveal the mechanism of &#8220;metabolic reprogramming&#8221; in phenotypic switching of fibroblasts of PAH.<xref rid="ame212486-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> The phenomenon of lipid accumulation was observed in the right ventricle of mice with bone morphogenetic protein receptor&#8208;2 mutant,<xref rid="ame212486-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> and a specific cholesterol metabolic pathway was described in the lungs of patients with PAH using a metabolomics technology.<xref rid="ame212486-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> The metabolic profile of PAH was strongly associated with survival and should be considered as part of the deep phenotypic feature of PAH.<xref rid="ame212486-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>
</p><p>We have also been conducting metabolomics studies of PAH in recent years. We reported that the higher spermine correlated with the clinical phenotype of patients with idiopathic PAH and promoted pulmonary vascular remodeling, and inhibition of spermine synthesis was a potentially promising strategy to prevent and treat PAH.<xref rid="ame212486-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="ame212486-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> Characteristics of plasma metabolome in the perioperative period of defect repair in patients with PAH associated with congenital heart disease were described.<xref rid="ame212486-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> Metabolic reprogramming of the urea cycle pathway occurred in rats with monocrotaline&#8208;induced experimental PAH.<xref rid="ame212486-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> Plasma metabolomics profiles in the circulatory system could be used to differentiate rodent models of PAH and idiopathic PAH.<xref rid="ame212486-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>
</p><p>Pulmonary artery smooth muscle cells (PASMC) are one of the major contributors to the pathological vascular remodeling of PAH.<xref rid="ame212486-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> In the process of vascular remodeling, PASMCs are transformed from contractile phenotype to synthetic phenotype, specifically manifested in malignant proliferation and migration like tumor cells.<xref rid="ame212486-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="ame212486-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> During the process of this malignant proliferation, cellular metabolism is significantly altered.<xref rid="ame212486-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="ame212486-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> Increasing evidence suggests that metabolic abnormalities play a key regulatory role in pulmonary vascular remodeling. However, to our knowledge, there have been no reports of metabolome changes in the supernatants of PASMCs. The aim of our current study is to analyze the metabolome in the culture supernatants of PASMCs during the malignant proliferation phenotype transition via targeted metabolomics, hoping to provide new insights into the understanding of pulmonary vascular remodeling.</p></sec><sec sec-type="materials-and-methods" id="ame212486-sec-0006"><label>2</label><title>MATERIALS AND METHODS</title><sec id="ame212486-sec-0007"><label>2.1</label><title>Cell culture and maintenance</title><p>Human PASMCs were purchased from ScienCell Research Laboratories (San Diego, CA, USA) and maintained according to the manufacturer's instructions. Briefly, the cells were cultured and maintained in Dulbecco's modified Eagles medium/Nutrient Mixture F&#8208;12 (DMEM/F12, Thermo Fisher Scientific, Waltham, USA) with 10% fetal calf serum (FBS, Thermo Fisher Scientific) at 37&#176;C with 5% CO<sub>2</sub>. Cells used in this study were from passages 6&#8211;8.</p></sec><sec id="ame212486-sec-0008"><label>2.2</label><title>Cell viability and proliferation assays</title><p>Human PASMCs were seeded at 1&#8201;&#215;&#8201;10<sup>4</sup> cells per well with complete medium in 96&#8208;well plates and incubated at 37&#176;C with 5% CO<sub>2</sub> for 24&#8201;h. The cells were then serum starved in DMEM/F12 without FBS for another 24&#8201;h. Culture supernatants were discarded and replaced with DMEM/F12 with 20&#8201;ng/mL of human PDGF&#8208;BB (220&#8208;BB&#8208;050, R&amp;D Systems, MN, USA) or vehicle. After incubation at 37&#176;C with 5% CO<sub>2</sub> for 24 or 48&#8201;h, cell viability and proliferation assays were performed as in our previous study.<xref rid="ame212486-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> Briefly, to assess cell viability, culture supernatants were discarded and replaced with CCK&#8208;8 solution (Dojindo Molecular Technologies Inc, Kumamoto, Japan), and the cells were incubated at 37&#176;C with 5% CO<sub>2</sub> for 1.5&#8201;h. Optical density (OD) was then determined at 450&#8201;nm using a microplate reader (Infinite M200 Pro, Tecan, Switzerland). To assess cell proliferation, culture supernatants were discarded, and cells were incubated with 0.1% crystal violet for 10&#8201;min at room temperature. The cells were washed thrice, and 100&#8201;&#956;L of 1% sodium dodecyl sulfate was added to each well. The plates were gently shaken to dissolve the dye thoroughly in an enzyme&#8208;linked immunosorbent detector for 10&#8201;min at room temperature. OD was determined at 570&#8201;nm.</p><p>To confirm cell proliferation, 5&#8208;ethynyl&#8208;2&#8242;&#8208;deoxyuridine (EdU) experiment was adopted. PASMCs were cultured in 96&#8208;well plates and treated with 100&#8201;&#956;L of medium containing 20&#8201;&#956;M of EdU. After incubation at 37&#176;C, with 5% CO<sub>2</sub> for 2&#8201;h, the cells were fixed with 4% paraformaldehyde for 30&#8201;min and incubated with 0.5% Triton X&#8208;100 in phosphate&#8208;buffered saline (PBS) for 20&#8201;min. The nuclei were stained with Hoechst dye 33&#8201;342. The rate of proliferation was calculated according to the manufacturer's instructions (KeyFluor488 Click&#8208;iT EdU Kit, keyGEN BioTECH, Jiangsu, China). Images of five randomly selected areas of each group were obtained using a fluorescence microscope (Leica, Wetzlar, Germany).</p></sec><sec id="ame212486-sec-0009"><label>2.3</label><title>Automated wound healing assay</title><p>Human PASMC migration was evaluated by a wound healing assay using an IncuCyte ZOOM imaging system (Essen Bioscience, Ann Arbor, USA), as described previously.<xref rid="ame212486-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> Briefly, the cells were seeded in 96&#8208;well plates at 1.5&#8201;&#215;&#8201;10<sup>4</sup> cells per well. After 24&#8201;h of serum starvation, the monolayers were scratched using a 96&#8208;Well Wound Maker apparatus (Essen Bioscience) to form an ~600&#8208;&#956;m&#8208;wide wound. To remove debris, cells were washed twice with PBS prior to administration of the vehicle (DMEM/F12 without FBS), or 20&#8201;ng/mL of PDGF&#8208;BB. The wound healing assay was then conducted using the IncuCyte ZOOM imaging system (Essen Bioscience) that automatically and continuously acquires and analyzes images using bright field microscopy, providing informative and real&#8208;time kinetic data. Cell migration rates are reported as the relative wound density calculated using an algorithm measuring cell density in the wound area relative to the cell density outside of the wound area at intervals of 1&#8201;h. Representative images were obtained at 100&#215; magnification at 0, 12, and 24&#8201;h postscratching.</p></sec><sec id="ame212486-sec-0010"><label>2.4</label><title>Metabolomics</title><p>To obtain sufficient samples to be tested, human PASMCs were inoculated in 12&#8208;well plates. After 48&#8201;h of PDGF&#8208;BB or vehicle induction, the cell supernatants were collected in 2&#8208;mL storage tubes. The tubes were immediately frozen in liquid nitrogen and stored at &#8722;80&#176;C until further analysis to avoid potential degradation of the analytes.</p><p>Metabolomics profiling was performed using liquid chromatography&#8211;mass spectrometry (LC&#8211;MS). The method provided the quantitative assessment of 121 metabolites covering the core network of energy, amino acid, amine, and nucleotide metabolisms, which were referenced to standard curves. The metabolites were identified based on mass and fragmentation analyses, and the full details of the methodology for the LC&#8211;MS conditions for metabolite analyses were as described previously.<xref rid="ame212486-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>
</p><p>Briefly, 100&#8201;&#956;L of cellular supernatant was mixed with 20&#8201;&#956;L of a reducing agent, 20&#8201;&#956;L of polar metabolite internal standards, and 400&#8201;&#956;L of acetonitrile, and the mixture was incubated for 15&#8201;min at 4&#176;C. The mixture was centrifuged at 13&#8201;000&#8201;rpm for 10&#8201;min, and the supernatant was transferred into a glass tube and dried under a gentle stream of nitrogen; 100&#8201;&#956;L of methanol&#8211;acetonitrile (75/25, v/v) was added and dissolved using ultrasound concussion and then centrifuged at 13&#8201;000&#8201;rpm for 10&#8201;min at 4&#176;C. The supernatant was isolated and subjected to targeted metabolite analysis. Chromatographic separation was conducted using a Waters X Bridge Amide column (21&#8201;&#215;&#8201;100&#8201;mm, 3.5&#8208;&#956;m particle size, Waters, Milford, MA). Mobile phase A consisted of 50% acetonitrile containing 15&#8201;mM ammonium acetate and 0.2% ammonium hydroxide, and mobile phase B consisted of acetonitrile&#8211;water (95:5, v/v) containing 15&#8201;mM ammonium acetate and 0.2% ammonium hydroxide. The gradient procedure was performed as follows: 0&#8211;10&#8201;min, 100% B; 10&#8211;23&#8201;min, 100%&#8211;0% B; 23&#8211;24&#8201;min, 0%&#8211;100% B; and 24&#8211;30&#8201;min, 100% B. The flow rate was 0.3&#8201;mL/min. The column temperature was 35&#176;C. The injection volume was 5&#8201;&#956;L, and the injection temperature was 4&#176;C.</p></sec><sec id="ame212486-sec-0011"><label>2.5</label><title>Statistical analysis</title><p>Student's <italic toggle="yes">t&#8208;</italic>test was applied to compare the differences between the two groups. The metabolites with fold change (FC) more than 1.2 and <italic toggle="yes">p&#8208;</italic>value&#8201;&lt;&#8201;0.05 were considered to be significantly altered. Partial least squares discriminant analysis (PLS&#8208;DA) was used to discriminate different groups. Variable importance in projection is a weighted sum of squares of the PLS loadings, which is a reflection of the importance of the metabolite. R2Y (cum) and Q2 (cum) values were calculated, respectively, to assess the stability and predictability of the established PLS&#8208;DA model. The pathway analysis with the pathway topology analysis was used to identify the most relevant pathways involved in the hyperproliferative PASMCs. Statistical analysis was performed using IBM SPSS Statistics 22 (International Business Machines Corporation, NY), SIMCA&#8208;P software (Umetrics, Umea, Sweden), and R programming (version 3.4.3) with R Studio.</p></sec></sec><sec sec-type="results" id="ame212486-sec-0012"><label>3</label><title>RESULTS</title><sec id="ame212486-sec-0013"><label>3.1</label><title>Phenotypic switch of human <styled-content style="fixed-case" toggle="no">PASMCs</styled-content> induced by <styled-content style="fixed-case" toggle="no">PDGF</styled-content>&#8208;<styled-content style="fixed-case" toggle="no">BB</styled-content>
</title><p>To mimic the phenotypic transition of human PASMCs under pathological conditions, we induced the cells with human PDGF&#8208;BB. The results of the CCK&#8208;8 assay showed that the cell viability of human PASMCs significantly increased 24 and 48&#8201;h after PDGF&#8208;BB stimulation (Figure&#160;<xref rid="ame212486-fig-0001" ref-type="fig">1A</xref>). Typically, an increase in cell viability was accompanied by enhanced proliferation. We then verified the proliferation of human PASMCs, as shown in Figure&#160;<xref rid="ame212486-fig-0001" ref-type="fig">1B</xref>; the cell proliferation of human PASMCs significantly increased 24 and 48&#8201;h after PDGF&#8208;BB stimulation, which was consistent with its viability.</p><fig position="float" fig-type="FIGURE" id="ame212486-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Cell viability and proliferation of human PASMCs (pulmonary artery smooth muscle cells) induced by PDGF&#8208;BB. (A) The cell viability of human PASMCs significantly increased below 20&#8201;ng/mL of PDGF&#8208;BB induction at either 24 or 48&#8201;h. (B) The cell proliferation of human PASMCs significantly increased below 20&#8201;ng/mL of PDGF&#8208;BB induction at either 24 or 48&#8201;h using crystal violet staining analysis. (C) Representative images with Edu staining of human PASMCs induced by PDGF&#8208;BB or vehicle for 24 and 48&#8201;h. Red represents Edu, and blue represents nucleus. The scale is 100&#8201;&#956;m. (D) Statistical analysis for cell proliferation of human PASMCs by Edu staining images. <italic toggle="yes">n</italic>&#8201;=&#8201;5 per group, ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, one&#8208;way analysis of variance (ANOVA), Tukey's post hoc test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="AME2-8-1268-g006.jpg"/></fig><p>Disordered migration of smooth muscle cells is also one of the major phenotypes of the vascular remodeling process in PAH. We used an automated imaging system to examine the dynamic process of migration of human PASMCs. Representative images showed that the migration of human PASMCs incubated with 20&#8201;ng/mL of PDGF&#8208;BB increased significantly compared to that incubated with vehicle after scratching monolayers at 12 and 24&#8201;h, respectively (Figure&#160;<xref rid="ame212486-fig-0002" ref-type="fig">2A</xref>). By continuously recording and analyzing wound confluency, we found that the migration rate of human PASMCs was maintained at a relatively low level within 24&#8201;h, whereas the migration rate of human PASMCs exposed to PDGF&#8208;BB stimulation gradually increased over the same time period (Figure&#160;<xref rid="ame212486-fig-0002" ref-type="fig">2B</xref>).</p><fig position="float" fig-type="FIGURE" id="ame212486-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Cell migration of human PASMCs (pulmonary artery smooth muscle cells) induced by PDGF&#8208;BB. (A) Representative images obtained at 100&#215; magnification at 0, 12 and 24&#8201;h after scratching monolayers using a 96&#8208;Well Wound Maker apparatus. (B) Real&#8208;time kinetic curve of wound confluency induced by 20&#8201;ng/mL of PDGF&#8208;BB or vehicle for 1&#8211;24&#8201;h. <italic toggle="yes">n</italic>&#8201;=&#8201;6 per group, ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, two&#8208;way repeated&#8208;measures analysis of variance (ANOVA).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="AME2-8-1268-g007.jpg"/></fig></sec><sec id="ame212486-sec-0014"><label>3.2</label><title>Metabolic profile in culture supernatants of human <styled-content style="fixed-case" toggle="no">PASMCs</styled-content>
</title><p>Score plots generated in PLS&#8208;DA showed a distinct classification, indicated as the PDGF&#8208;BB group (human PASMCs exposed to PDGF&#8208;BB) cluster on the right side and the control group (human PASMCs exposed to vehicle) on the left (Figure&#160;<xref rid="ame212486-fig-0003" ref-type="fig">3</xref>). A heat map consisting of 121 metabolites was obtained, and it demonstrated the overall change characteristics of these metabolites (Figure&#160;<xref rid="ame212486-fig-0004" ref-type="fig">4</xref>). Red represents upregulation of metabolites, whereas blue represents downregulation on the heat map, indicating a profound systemic alteration in supernatants of proliferative PASMCs induced by PDGF&#8208;BB. The original metabolite levels in PDGF&#8208;BB&#8208;treated or vehicle&#8208;treated PASMCs are presented in Table&#160;<xref rid="ame212486-supitem-0001" ref-type="supplementary-material">S1</xref>.</p><fig position="float" fig-type="FIGURE" id="ame212486-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Three&#8208;dimensional score plots show a distinct classification in the supernatant of human pulmonary artery smooth muscle cells (PASMC) treated with 20&#8201;ng/mL of PDGF&#8208;BB or vehicle. Each plot represents an individual sample from each group.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="AME2-8-1268-g004.jpg"/></fig><fig position="float" fig-type="FIGURE" id="ame212486-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>Heat map obtained using liquid chromatography&#8211;mass spectrometry from cellular supernatant, showing differences in the metabolite signatures of human pulmonary artery smooth muscle cells (PASMC) treated with 20&#8201;ng/mL of PDGF&#8208;BB or vehicle. Each column represents an individual sample from each group. A total of 121 metabolites were identified. The color intensity is proportional to the fold change of the ratio, and the numbers represent numerization.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-9" orientation="portrait" xlink:href="AME2-8-1268-g003.jpg"/></fig></sec><sec id="ame212486-sec-0015"><label>3.3</label><title>Differential metabolites in culture supernatants of human <styled-content style="fixed-case" toggle="no">PASMCs</styled-content>
</title><p>Eleven metabolites were found to be significantly upregulated (FC &gt;1.20, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05), whereas seven metabolites were downregulated (FC &lt;0.83, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) in the supernatants of PASMCs induced by PDGF&#8208;BB compared to the vehicle&#8208;treated cells (Figure&#160;<xref rid="ame212486-fig-0005" ref-type="fig">5A</xref>). The heat map based on the relative content of metabolites showed the name and clustering of each differential metabolite. Adenosine, hydroxyphenylacetic acid, 5&#8242;&#8208;methylthioadenosine, creatinine, lactic acid, pyruvate, 2&#8208;dehydro&#8208;<sc>d</sc>&#8208;gluconate, cytosine, 2&#8242;&#8208;dexycytidine, 2,3&#8208;diphosphoglyceric acid, and methylnicotinamide increased significantly in the supernatant of PASMCs induced by PDGF&#8208;BB, whereas 7&#8208;methylguanosine, pantothenate, uridine, dihydroorotate, <italic toggle="yes">N</italic>&#8208;acetyl&#8208;<sc>l</sc>&#8208;lysine, 4&#8208;pyridoxic acid, and inosine decreased significantly (Figure&#160;<xref rid="ame212486-fig-0005" ref-type="fig">5B</xref>). The false discovery rate was also used to differentiate the metabolites between the two groups, which is shown in the volcano plot in Figure&#160;<xref rid="ame212486-supitem-0001" ref-type="supplementary-material">S1</xref>.</p><fig position="float" fig-type="FIGURE" id="ame212486-fig-0005" orientation="portrait"><label>FIGURE 5</label><caption><p>Volcano plot and heat map of significantly altered metabolites. (A) Volcano plot of metabolite changes in the metabolite signatures of culture supernatant from human pulmonary artery smooth muscle cells (PASMC) treated with 20&#8201;ng/mL of PDGF&#8208;BB or vehicle. Blue represents downregulation, gray represents no significant difference, and red represents upregulation. Each point represents a metabolite. (B) Heat map obtained from metabolic profiling of culture supernatant from human PASMCs treated with 20&#8201;ng/mL of PDGF&#8208;BB or vehicle. Each column represents an individual sample. Briefly, 7 metabolites were significantly downregulated and 11 were upregulated human PASMCs treated with 20&#8201;ng/mL of PDGF&#8208;BB compared to that treated with vehicle.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-11" orientation="portrait" xlink:href="AME2-8-1268-g001.jpg"/></fig></sec><sec id="ame212486-sec-0016"><label>3.4</label><title>Pathway enrichment analysis in culture supernatants of human <styled-content style="fixed-case" toggle="no">PASMCs</styled-content>
</title><p>The pathway analysis is shown in Figure&#160;<xref rid="ame212486-fig-0006" ref-type="fig">6A</xref> and Table&#160;<xref rid="ame212486-supitem-0001" ref-type="supplementary-material">S2</xref>. Generally, 14 pathways were involved, and pyruvate metabolism pathway was ranked first with an enrichment impact of 0.207 followed by glycolysis/gluconeogenesis and pyrimidine metabolism. Two metabolites, pyruvate (Figure&#160;<xref rid="ame212486-fig-0006" ref-type="fig">6B</xref>) and lactic acid (Figure&#160;<xref rid="ame212486-fig-0006" ref-type="fig">6C</xref>), contributed to pyruvate metabolism pathway and were significantly changed between the PDGF&#8208;BB group and control group. Three metabolites enriched in glycolysis/gluconeogenesis pathway, including pyruvate (Figure&#160;<xref rid="ame212486-fig-0006" ref-type="fig">6B</xref>), lactic acid (Figure&#160;<xref rid="ame212486-fig-0006" ref-type="fig">6C</xref>), and 2,3&#8208;diphosphoglyceric acid (Figure&#160;<xref rid="ame212486-fig-0006" ref-type="fig">6D</xref>), and another three metabolites enriched in pyrimidine metabolism pathway, including dihydroorotate (Figure&#160;<xref rid="ame212486-fig-0006" ref-type="fig">6E</xref>), uridine (Figure&#160;<xref rid="ame212486-fig-0006" ref-type="fig">6F</xref>), and 2&#8242;&#8208;dexycytidine (Figure&#160;<xref rid="ame212486-fig-0006" ref-type="fig">6G</xref>), were significantly changed between the PDGF&#8208;BB group and control group. Furthermore, glycine, serine, and threonine metabolism pathway and cysteine and methionine metabolism pathway with a <italic toggle="yes">p&#8208;</italic>value&#8201;&lt;&#8201;0.05 were considered as metabolic pathways with significant changes in cultured supernatants of PDGF&#8208;BB&#8208;treated PASMCs compared to control cells.</p><fig position="float" fig-type="FIGURE" id="ame212486-fig-0006" orientation="portrait"><label>FIGURE 6</label><caption><p>(A) The significantly changed metabolic pathways in culture supernatant of human pulmonary artery smooth muscle cells (PASMC) treated with 20&#8201;ng/mL of PDGF&#8208;BB or vehicle, which were identified using metabolite set enrichment analysis. Pyruvate metabolism pathway was ranked first based on the pathway impact. Concentrations of differential metabolites, (B) pyruvate, (C) lactic acid, (D) 2,3&#8208;diphosphoglyceric acid, (E) dihydroorotate, (F) uridine, and (G) 2&#8242;&#8208;dexycytidine, in culture supernatant of human PASMCs treated with 20&#8201;ng/mL of PDGF&#8208;BB or vehicle, which contributed to the significantly changed metabolic pathways of pyruvate metabolism, glycolysis/gluconeogenesis, and pyrimidine metabolism. Data are shown as box plots and violin plots, <italic toggle="yes">n</italic>&#8201;=&#8201;3 per group; *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01, and ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, Student's <italic toggle="yes">t</italic>&#8208;test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-13" orientation="portrait" xlink:href="AME2-8-1268-g002.jpg"/></fig></sec></sec><sec sec-type="discussion" id="ame212486-sec-0017"><label>4</label><title>DISCUSSION</title><p>Abnormal metabolic regulation is a pivotal factor in mediating pulmonary vascular remodeling, and in recent years, numerous metabolomics studies have been conducted to elucidate the intricate mechanisms underlying the metabolic regulation in PAH.<xref rid="ame212486-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="ame212486-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> Certain biomarkers have been suggested, and numerous regulatory pathways have been identified, both of which have indisputably enhanced our comprehension of the intricate pathological mechanism underlying PAH.</p><p>In the current metabolomics investigations, blood samples from patients are the most commonly utilized sample type, with lung tissue from certain animal models taking a secondary yet still significant role. Our previous research emphasized the fact that hypoxia and potent mitogens trigger the expression of metabolism&#8208;associated genes in PASMCs.<xref rid="ame212486-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>, <xref rid="ame212486-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> However, there remains a lack of clarity regarding the specific alterations in the extracellular metabolites secreted by PASMCs as they transition from their contractile phenotype to a synthetic phenotype. In our study, we established a classic PASMC model and evaluated the cell proliferation and migration induced by PDGF&#8208;BB, and confirmed that the transformation of phenotype occurred in PASMCs. Therefore, we collected the cell supernatants and carried out targeted metabolomics analysis. We found that the metabolome in the cell supernatants changed widely during the phenotypic transformation of PASMCs. A total of 18 metabolites in the supernatants of PASMCs changed significantly. Of these, the concentrations of 11 metabolites were upregulated, whereas those of 7 metabolites were downregulated. Further analysis of pathway enrichment showed that five metabolic pathways had changed significantly.</p><p>Among these significantly changed metabolic pathways, pyruvate metabolism pathway ranked first due to its highest impact. Pyruvate metabolism has been recently considered to play a regulatory role in pulmonary vascular remodeling. A pyruvate dehydrogenase kinase&#8211;dependent shift in mitochondrial metabolism promoted right ventricular fibrosis in PAH.<xref rid="ame212486-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> A clinical trial revealed that the inhibition of pyruvate dehydrogenase kinase improved PAH in genetically susceptible patients.<xref rid="ame212486-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> Pyruvate kinase M2 played a key role in the process of MicroRNA&#8208;124 enhancing endothelial cell glycolysis.<xref rid="ame212486-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> The metabolic and proliferative states of vascular adventitial fibroblasts in PAH were regulated through a MicroRNA&#8208;124/PTBP1 (polypyrimidine tract binding protein 1)/pyruvate kinase muscle axis.<xref rid="ame212486-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> These studies focused on pyruvate kinase and revealed the role of the pyruvate metabolism pathway in the process of PAH. Our study is the first to demonstrate the alterations in pyruvate metabolism from the perspective of PASMC phenotypic transformation, reinforcing the notion that targeting this critical pathway holds immense potential as a therapeutic strategy.</p><p>Another important metabolic pathway, glycolysis/gluconeogenesis, pathway was found to be significantly altered in our proliferation model. Glycolytic shift has been considered to be related to the mechanism of PAH. Similar to the Warburg effect in cancer, a shift from mitochondrial oxidation to glycolysis occurs in reconstructed pulmonary vessels and the right ventricle.<xref rid="ame212486-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> A recent study showed that 6&#8208;phosphofructo&#8208;2&#8208;kinase/fructose&#8208;2,6&#8208;bisphosphatase 3 (PFKFB3)&#8211;mediated endothelial glycolysis aggravated PAH.<xref rid="ame212486-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> Another study revealed that upregulated PFKFB3 mediated collagen synthesis and proliferation of PASMCs through the elevation of glycolysis and lactate.<xref rid="ame212486-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref> Our research has further elucidated that glycolysis pathway plays a pivotal role in PAH, corroborating the findings of previous literature. Additionally, we have made an interesting observation, being the first to observe a marked elevation in 2,3&#8208;diphosphoglyceric acid during the phenotypic transformation of PASMCs. As we know, 2,3&#8208;diphosphoric acid is an upstream precursor in glycolysis<xref rid="ame212486-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref>; therefore, reducing the concentration of 2,3&#8208;diphosphoric acid may also be a potential prevention and treatment strategy for PAH.</p><p>It is evident that our current research still encounters certain limitations. Notably, the significantly altered metabolites have yet to undergo validation in animal models of PAH, including those induced by monocrotaline in rats and by Sugen5416 + hypoxia. Furthermore, the functional role of key metabolic pathways in the process of pulmonary vascular remodeling remains unconfirmed. Therefore, it is imperative to focus on elucidating the pathological functions and mechanisms underlying these differential metabolites and metabolic pathways in future research endeavors.</p><p>Our study reveals the characteristics of metabolome in the cell supernatant during the transformation of PASMCs from contractile phenotype to synthetic phenotype. As PASMCs undergo tumor&#8208;like proliferation and migration, a profound alteration in extracellular metabolites was observed. Notably, pyruvate metabolism emerged as a potential metabolic pathway that significantly contributed to regulating the phenotypic shift of smooth muscle cells in the context of pulmonary vascular remodeling.</p></sec><sec id="ame212486-sec-0020"><title>AUTHOR CONTRIBUTIONS</title><p>
<bold>Meng&#8208;Jie Zhang:</bold> Data curation; formal analysis; investigation; writing &#8211; original draft. <bold>Jie&#8208;Jian Kou:</bold> Data curation; formal analysis; investigation. <bold>Hong&#8208;Da Zhang:</bold> Formal analysis; software. <bold>Xin&#8208;Mei Xie:</bold> Methodology; visualization. <bold>Yun&#8208;Feng Zhou:</bold> Software; visualization. <bold>Ping Yuan:</bold> Methodology; software. <bold>Xiao&#8208;Bin Pang:</bold> Resources; visualization. <bold>Lu&#8208;Ling Zhao:</bold> Conceptualization; investigation; project administration. <bold>Jing Qiu:</bold> Conceptualization; project administration; supervision. <bold>Yang&#8208;Yang He:</bold> Conceptualization; funding acquisition; project administration; resources; writing &#8211; review and editing.</p></sec><sec id="ame212486-sec-0018"><title>FUNDING INFORMATION</title><p>This study was funded by the Projects of National Natural Science Foundation of China (82&#8201;170&#8201;058, 82&#8201;241&#8201;007), the Special Project for Key R&amp;D and Promotion of Henan Province (232&#8201;102&#8201;311&#8201;233, 242&#8201;102&#8201;311&#8201;034), and the Joint Fund of Science and Technology R&amp;D Plan of Henan Province (232103810056).</p></sec><sec sec-type="COI-statement" id="ame212486-sec-0019"><title>CONFLICT OF INTEREST STATEMENT</title><p>The authors declare that they have no conflicts of interest.</p></sec><sec id="ame212486-sec-0830"><title>ETHICAL STATEMENT</title><p>This study was approved by the Ethics Committee of Henan University (ethics approval number: HUSOM2021&#8208;058).</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="ame212486-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
Data S1:
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="AME2-8-1268-s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="ame212486-sec-0527"><title>ACKNOWLEDGMENTS</title><p>None.</p></ack><ref-list content-type="cited-references" id="ame212486-bibl-0001"><title>REFERENCES</title><ref id="ame212486-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="ame212486-cit-0001"><string-name name-style="western"><surname>Humbert</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kovacs</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Hoeper</surname><given-names>MM</given-names></string-name>. <article-title>Et al; ESC/ERS scientific document group. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension</article-title>. <source>Eur Heart J</source>. <year>2022</year>;<volume>43</volume>(<issue>38</issue>):<fpage>3618</fpage>&#8208;<lpage>3731</lpage>.<pub-id pub-id-type="pmid">36017548</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehac237</pub-id></mixed-citation></ref><ref id="ame212486-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="ame212486-cit-0002"><string-name name-style="western"><surname>Hassoun</surname><given-names>PM</given-names></string-name>. <article-title>Pulmonary arterial Hypertension</article-title>. <source>N Engl J Med</source>. <year>2021</year>;<volume>385</volume>(<issue>25</issue>):<fpage>2361</fpage>&#8208;<lpage>2376</lpage>.<pub-id pub-id-type="pmid">34910865</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMra2000348</pub-id></mixed-citation></ref><ref id="ame212486-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="ame212486-cit-0003"><string-name name-style="western"><surname>Poch</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Mandel</surname><given-names>J</given-names></string-name>. <article-title>Pulmonary hypertension</article-title>. <source>Ann Intern Med</source>. <year>2021</year>;<volume>174</volume>:<fpage>ITC49</fpage>&#8208;<lpage>ITC64</lpage>.<pub-id pub-id-type="pmid">33844574</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/AITC202104200</pub-id></mixed-citation></ref><ref id="ame212486-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="ame212486-cit-0004"><string-name name-style="western"><surname>Benza</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname><given-names>DP</given-names></string-name>, <string-name name-style="western"><surname>Barst</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Badesch</surname><given-names>DB</given-names></string-name>, <string-name name-style="western"><surname>Frost</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>McGoon</surname><given-names>MD</given-names></string-name>. <article-title>An evaluation of long&#8208;term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry</article-title>. <source>Chest</source>. <year>2012</year>;<volume>142</volume>(<issue>2</issue>):<fpage>448</fpage>&#8208;<lpage>456</lpage>.<pub-id pub-id-type="pmid">22281797</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1378/chest.11-1460</pub-id></mixed-citation></ref><ref id="ame212486-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="ame212486-cit-0005"><string-name name-style="western"><surname>McLaughlin</surname><given-names>VV</given-names></string-name>, <string-name name-style="western"><surname>Hoeper</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Channick</surname><given-names>RN</given-names></string-name>, et&#160;al. <article-title>Pulmonary arterial Hypertension&#8208;related morbidity is prognostic for mortality</article-title>. <source>J Am Coll Cardiol</source>. <year>2018</year>;<volume>71</volume>(<issue>7</issue>):<fpage>752</fpage>&#8208;<lpage>763</lpage>.<pub-id pub-id-type="pmid">29447737</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2017.12.010</pub-id></mixed-citation></ref><ref id="ame212486-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="ame212486-cit-0006"><string-name name-style="western"><surname>Wu</surname><given-names>XH</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>YY</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>ZR</given-names></string-name>, et&#160;al. <article-title>Single&#8208;cell analysis of peripheral blood from high&#8208;altitude pulmonary hypertension patients identifies a distinct monocyte phenotype</article-title>. <source>Nat Commun</source>. <year>2023</year>;<volume>14</volume>(<issue>1</issue>):<fpage>1820</fpage>.<pub-id pub-id-type="pmid">37002243</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-37527-4</pub-id><pub-id pub-id-type="pmcid">PMC10066231</pub-id></mixed-citation></ref><ref id="ame212486-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="ame212486-cit-0007"><string-name name-style="western"><surname>Yan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>YY</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>X</given-names></string-name>, et&#160;al. <article-title>DNA methyltransferase 3B deficiency unveils a new pathological mechanism of pulmonary hypertension</article-title>. <source>Sci Adv</source>. <year>2020</year>;<volume>6</volume>(<issue>50</issue>):<elocation-id>eaba2470</elocation-id>.<pub-id pub-id-type="pmid">33298433</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.aba2470</pub-id><pub-id pub-id-type="pmcid">PMC7725449</pub-id></mixed-citation></ref><ref id="ame212486-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="ame212486-cit-0008"><string-name name-style="western"><surname>Liu</surname><given-names>SF</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>Y</given-names></string-name>. <article-title>Animal models of pulmonary hypertension due to left heart disease</article-title>. <source>Animal Model Exp Med</source>. <year>2022</year>;<volume>5</volume>:<fpage>197</fpage>&#8208;<lpage>206</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ame2.12214</pub-id><pub-id pub-id-type="pmid">35234367</pub-id><pub-id pub-id-type="pmcid">PMC9240728</pub-id></mixed-citation></ref><ref id="ame212486-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="ame212486-cit-0009"><string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>JZ</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>Regulatory T cell&#8208;related gene indicators in pulmonary Hypertension</article-title>. <source>Front Pharmacol</source>. <year>2022</year>;<volume>31</volume>(<issue>13</issue>):<elocation-id>908783</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2022.908783</pub-id><pub-id pub-id-type="pmcid">PMC9197497</pub-id><pub-id pub-id-type="pmid">35712711</pub-id></mixed-citation></ref><ref id="ame212486-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="ame212486-cit-0010"><string-name name-style="western"><surname>Lewis</surname><given-names>GD</given-names></string-name>, <string-name name-style="western"><surname>Ngo</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Hemnes</surname><given-names>AR</given-names></string-name>, et&#160;al. <article-title>Metabolic profiling of right ventricular&#8208;pulmonary vascular function reveals circulating biomarkers of pulmonary Hypertension</article-title>. <source>J Am Coll Cardiol</source>. <year>2016</year>;<volume>67</volume>(<issue>2</issue>):<fpage>174</fpage>&#8208;<lpage>189</lpage>.<pub-id pub-id-type="pmid">26791065</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2015.10.072</pub-id><pub-id pub-id-type="pmcid">PMC4962613</pub-id></mixed-citation></ref><ref id="ame212486-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="ame212486-cit-0011"><string-name name-style="western"><surname>Li</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Riddle</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name>, et&#160;al. <article-title>Metabolic reprogramming regulates the proliferative and inflammatory phenotype of adventitial fibroblasts in pulmonary Hypertension through the transcriptional corepressor C&#8208;terminal binding Protein&#8208;1</article-title>. <source>Circulation</source>. <year>2016</year>;<volume>134</volume>(<issue>15</issue>):<fpage>1105</fpage>&#8208;<lpage>1121</lpage>.<pub-id pub-id-type="pmid">27562971</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.116.023171</pub-id><pub-id pub-id-type="pmcid">PMC5069179</pub-id></mixed-citation></ref><ref id="ame212486-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="ame212486-cit-0012"><string-name name-style="western"><surname>Talati</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Brittain</surname><given-names>EL</given-names></string-name>, <string-name name-style="western"><surname>Fessel</surname><given-names>JP</given-names></string-name>, et&#160;al. <article-title>Mechanisms of lipid accumulation in the bone morphogenetic protein receptor type 2 mutant right ventricle</article-title>. <source>Am J Respir Crit Care Med</source>. <year>2016</year>;<volume>194</volume>(<issue>6</issue>):<fpage>719</fpage>&#8208;<lpage>728</lpage>.<pub-id pub-id-type="pmid">27077479</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.201507-1444OC</pub-id><pub-id pub-id-type="pmcid">PMC5027228</pub-id></mixed-citation></ref><ref id="ame212486-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="ame212486-cit-0013"><string-name name-style="western"><surname>Zhao</surname><given-names>YD</given-names></string-name>, <string-name name-style="western"><surname>Yun</surname><given-names>HZH</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>De novo synthesize of bile acids in pulmonary arterial hypertension lung</article-title>. <source>Metabolomics</source>. <year>2014</year>;<volume>10</volume>(<issue>6</issue>):<fpage>1169</fpage>&#8208;<lpage>1175</lpage>.<pub-id pub-id-type="pmid">25374487</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11306-014-0653-y</pub-id><pub-id pub-id-type="pmcid">PMC4213391</pub-id></mixed-citation></ref><ref id="ame212486-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="ame212486-cit-0014"><string-name name-style="western"><surname>Rhodes</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Ghataorhe</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Wharton</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Plasma metabolomics implicates modified transfer RNAs and altered bioenergetics in the outcomes of pulmonary arterial Hypertension</article-title>. <source>Circulation</source>. <year>2017</year>;<volume>135</volume>(<issue>5</issue>):<fpage>460</fpage>&#8208;<lpage>475</lpage>.<pub-id pub-id-type="pmid">27881557</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.116.024602</pub-id><pub-id pub-id-type="pmcid">PMC5287439</pub-id></mixed-citation></ref><ref id="ame212486-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="ame212486-cit-0015"><string-name name-style="western"><surname>He</surname><given-names>YY</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>X</given-names></string-name>, et&#160;al. <article-title>Spermine promotes pulmonary vascular remodelling and its synthase is a therapeutic target for pulmonary arterial hypertension</article-title>. <source>Eur Respir J</source>. <year>2020</year>;<volume>56</volume>(<issue>5</issue>):<elocation-id>2000522</elocation-id>.<pub-id pub-id-type="pmid">32513782</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1183/13993003.00522-2020</pub-id></mixed-citation></ref><ref id="ame212486-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="ame212486-cit-0016"><string-name name-style="western"><surname>Rhodes</surname><given-names>CJ</given-names></string-name>. <article-title>The cancer hypothesis of pulmonary arterial hypertension: are polyamines the new Warburg?</article-title><source>Eur Respir J</source>. <year>2020</year>;<volume>56</volume>(<issue>5</issue>):<elocation-id>2002350</elocation-id>.<pub-id pub-id-type="pmid">33154079</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1183/13993003.02350-2020</pub-id></mixed-citation></ref><ref id="ame212486-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="ame212486-cit-0017"><string-name name-style="western"><surname>He</surname><given-names>YY</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>JW</given-names></string-name>, et&#160;al. <article-title>Plasma metabolomics in the perioperative period of defect repair in patients with pulmonary arterial hypertension associated with congenital heart disease</article-title>. <source>Acta Pharmacol Sin</source>. <year>2022</year>;<volume>43</volume>(<issue>7</issue>):<fpage>1710</fpage>&#8208;<lpage>1720</lpage>.<pub-id pub-id-type="pmid">34848852</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41401-021-00804-3</pub-id><pub-id pub-id-type="pmcid">PMC9253009</pub-id></mixed-citation></ref><ref id="ame212486-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="ame212486-cit-0018"><string-name name-style="western"><surname>Zheng</surname><given-names>HK</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>Y</given-names></string-name>, et&#160;al. <article-title>Metabolic reprogramming of the urea cycle pathway in experimental pulmonary arterial hypertension rats induced by monocrotaline</article-title>. <source>Respir Res</source>. <year>2018</year>;<volume>19</volume>:<fpage>94</fpage>.<pub-id pub-id-type="pmid">29751839</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12931-018-0800-5</pub-id><pub-id pub-id-type="pmcid">PMC5948901</pub-id></mixed-citation></ref><ref id="ame212486-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="ame212486-cit-0019"><string-name name-style="western"><surname>Zhao</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>YY</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>SS</given-names></string-name>, et&#160;al. <article-title>Circulating plasma Metabolomic profiles differentiate rodent models of pulmonary Hypertension and idiopathic pulmonary arterial Hypertension patients</article-title>. <source>Am J Hypertens</source>. <year>2019</year>;<volume>32</volume>(<issue>11</issue>):<fpage>1109</fpage>&#8208;<lpage>1117</lpage>.<pub-id pub-id-type="pmid">31350549</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ajh/hpz121</pub-id></mixed-citation></ref><ref id="ame212486-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="ame212486-cit-0020"><string-name name-style="western"><surname>Lechartier</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Berrebeh</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Huertas</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Humbert</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Guignabert</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Tu</surname><given-names>L</given-names></string-name>. <article-title>Phenotypic diversity of vascular smooth muscle cells in pulmonary arterial Hypertension: implications for therapy</article-title>. <source>Chest</source>. <year>2022</year>;<volume>161</volume>(<issue>1</issue>):<fpage>219</fpage>&#8208;<lpage>231</lpage>.<pub-id pub-id-type="pmid">34391758</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chest.2021.08.040</pub-id></mixed-citation></ref><ref id="ame212486-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="ame212486-cit-0021"><string-name name-style="western"><surname>He</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Fang</surname><given-names>Z</given-names></string-name>. <article-title>The role and regulation of pulmonary artery smooth muscle cells in pulmonary Hypertension</article-title>. <source>Int J Hypertens</source>. <year>2020</year>;<volume>2020</volume>:<elocation-id>1478291</elocation-id>.<pub-id pub-id-type="pmid">32850144</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2020/1478291</pub-id><pub-id pub-id-type="pmcid">PMC7441461</pub-id></mixed-citation></ref><ref id="ame212486-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="ame212486-cit-0022"><string-name name-style="western"><surname>Han</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chandel</surname><given-names>NS</given-names></string-name>. <article-title>Lessons from cancer metabolism for pulmonary arterial Hypertension and fibrosis</article-title>. <source>Am J Respir Cell Mol Biol</source>. <year>2021</year>;<volume>65</volume>(<issue>2</issue>):<fpage>134</fpage>&#8208;<lpage>145</lpage>.<pub-id pub-id-type="pmid">33844936</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1165/rcmb.2020-0550TR</pub-id><pub-id pub-id-type="pmcid">PMC8399574</pub-id></mixed-citation></ref><ref id="ame212486-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="ame212486-cit-0023"><string-name name-style="western"><surname>Shi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>F</given-names></string-name>. <article-title>Metabolism of vascular smooth muscle cells in vascular diseases</article-title>. <source>Am J Physiol Heart Circ Physiol</source>. <year>2020</year>;<volume>319</volume>(<issue>3</issue>):<fpage>H613</fpage>&#8208;<lpage>H631</lpage>.<pub-id pub-id-type="pmid">32762559</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajpheart.00220.2020</pub-id></mixed-citation></ref><ref id="ame212486-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="ame212486-cit-0024"><string-name name-style="western"><surname>James</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zemskova</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Eccles</surname><given-names>CA</given-names></string-name>, et&#160;al. <article-title>Single mutation in the NFU1 gene metabolically reprograms pulmonary artery smooth muscle cells</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2021</year>;<volume>41</volume>(<issue>2</issue>):<fpage>734</fpage>&#8208;<lpage>754</lpage>.<pub-id pub-id-type="pmid">33297749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/ATVBAHA.120.314655</pub-id><pub-id pub-id-type="pmcid">PMC7837686</pub-id></mixed-citation></ref><ref id="ame212486-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="ame212486-cit-0025"><string-name name-style="western"><surname>Ahmad</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Mui</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Galbraith</surname><given-names>L</given-names></string-name>, et&#160;al. <article-title>Sleeping beauty screen reveals Pparg activation in metastatic prostate cancer</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2016</year>;<volume>113</volume>(<issue>29</issue>):<fpage>8290</fpage>&#8208;<lpage>8295</lpage>.<pub-id pub-id-type="pmid">27357679</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1601571113</pub-id><pub-id pub-id-type="pmcid">PMC4961202</pub-id></mixed-citation></ref><ref id="ame212486-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="ame212486-cit-0026"><string-name name-style="western"><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ren</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Dong</surname><given-names>Z</given-names></string-name>. <article-title>Targeted metabolomic profiling of cardioprotective effect of Ginkgo biloba L. extract on myocardial ischemia in rats</article-title>. <source>Phytomedicine</source>. <year>2016</year>;<volume>23</volume>(<issue>6</issue>):<fpage>621</fpage>&#8208;<lpage>631</lpage>.<pub-id pub-id-type="pmid">27161403</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phymed.2016.03.005</pub-id></mixed-citation></ref><ref id="ame212486-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="ame212486-cit-0027"><string-name name-style="western"><surname>Wang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>WJ</given-names></string-name>, et&#160;al. <article-title>The role of glutamine and Glutaminase in pulmonary Hypertension</article-title>. <source>Front Cardiovasc Med</source>. <year>2022</year>;<volume>9</volume>:<elocation-id>838657</elocation-id>.<pub-id pub-id-type="pmid">35310969</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcvm.2022.838657</pub-id><pub-id pub-id-type="pmcid">PMC8924297</pub-id></mixed-citation></ref><ref id="ame212486-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="ame212486-cit-0028"><string-name name-style="western"><surname>La Frano</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Fahrmann</surname><given-names>JF</given-names></string-name>, <string-name name-style="western"><surname>Grapov</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>Umbilical cord blood metabolomics reveal distinct signatures of dyslipidemia prior to bronchopulmonary dysplasia and pulmonary hypertension</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source>. <year>2018</year>;<volume>315</volume>(<issue>5</issue>):<fpage>L870</fpage>&#8208;<lpage>L881</lpage>.<pub-id pub-id-type="pmid">30113229</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajplung.00283.2017</pub-id><pub-id pub-id-type="pmcid">PMC6295510</pub-id></mixed-citation></ref><ref id="ame212486-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="ame212486-cit-0029"><string-name name-style="western"><surname>He</surname><given-names>YY</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>XM</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>HD</given-names></string-name>, et&#160;al. <article-title>Identification of hypoxia induced metabolism associated genes in pulmonary Hypertension</article-title>. <source>Front Pharmacol</source>. <year>2021</year>;<volume>12</volume>:<elocation-id>753727</elocation-id>.<pub-id pub-id-type="pmid">34803695</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2021.753727</pub-id><pub-id pub-id-type="pmcid">PMC8602807</pub-id></mixed-citation></ref><ref id="ame212486-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="ame212486-cit-0030"><string-name name-style="western"><surname>Yan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>P</given-names></string-name>, et&#160;al. <article-title>Implication of proliferation gene biomarkers in pulmonary hypertension</article-title>. <source>Animal Model Exp Med</source>. <year>2021</year>;<volume>4</volume>(<issue>4</issue>):<fpage>369</fpage>&#8208;<lpage>380</lpage>.<pub-id pub-id-type="pmid">34977488</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ame2.12191</pub-id><pub-id pub-id-type="pmcid">PMC8690983</pub-id></mixed-citation></ref><ref id="ame212486-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="ame212486-cit-0031"><string-name name-style="western"><surname>Tian</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Dasgupta</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Epigenetic metabolic reprogramming of right ventricular fibroblasts in pulmonary arterial Hypertension: a pyruvate dehydrogenase kinase&#8208;dependent shift in mitochondrial metabolism promotes right ventricular fibrosis</article-title>. <source>Circ Res</source>. <year>2020</year>;<volume>126</volume>(<issue>12</issue>):<fpage>1723</fpage>&#8208;<lpage>1745</lpage>.<pub-id pub-id-type="pmid">32216531</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCRESAHA.120.316443</pub-id><pub-id pub-id-type="pmcid">PMC7274861</pub-id></mixed-citation></ref><ref id="ame212486-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="ame212486-cit-0032"><string-name name-style="western"><surname>Michelakis</surname><given-names>ED</given-names></string-name>, <string-name name-style="western"><surname>Gurtu</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Webster</surname><given-names>L</given-names></string-name>, et&#160;al. <article-title>Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients</article-title>. <source>Sci Transl Med</source>. <year>2017</year>;<volume>9</volume>:<elocation-id>eaao4583</elocation-id>.<pub-id pub-id-type="pmid">29070699</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.aao4583</pub-id></mixed-citation></ref><ref id="ame212486-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="ame212486-cit-0033"><string-name name-style="western"><surname>Caruso</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Dunmore</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Schlosser</surname><given-names>K</given-names></string-name>, et&#160;al. <article-title>Identification of MicroRNA&#8208;124 as a major regulator of enhanced endothelial cell glycolysis in pulmonary arterial Hypertension via PTBP1 (Polypyrimidine tract binding protein) and pyruvate kinase M2</article-title>. <source>Circulation</source>. <year>2017</year>;<volume>136</volume>(<issue>25</issue>):<fpage>2451</fpage>&#8208;<lpage>2467</lpage>.<pub-id pub-id-type="pmid">28971999</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.117.028034</pub-id><pub-id pub-id-type="pmcid">PMC5736425</pub-id></mixed-citation></ref><ref id="ame212486-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="ame212486-cit-0034"><string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Metabolic and proliferative state of vascular adventitial fibroblasts in pulmonary Hypertension is regulated through a MicroRNA&#8208;124/PTBP1 (Polypyrimidine tract binding protein 1)/pyruvate kinase muscle Axis</article-title>. <source>Circulation</source>. <year>2017</year>;<volume>136</volume>(<issue>25</issue>):<fpage>2468</fpage>&#8208;<lpage>2485</lpage>.<pub-id pub-id-type="pmid">28972001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.117.028069</pub-id><pub-id pub-id-type="pmcid">PMC5973494</pub-id></mixed-citation></ref><ref id="ame212486-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="ame212486-cit-0035"><string-name name-style="western"><surname>Culley</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Chan</surname><given-names>SY</given-names></string-name>. <article-title>Mitochondrial metabolism in pulmonary hypertension: beyond mountains there are mountains</article-title>. <source>J Clin Invest</source>. <year>2018</year>;<volume>128</volume>(<issue>9</issue>):<fpage>3704</fpage>&#8208;<lpage>3715</lpage>.<pub-id pub-id-type="pmid">30080181</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI120847</pub-id><pub-id pub-id-type="pmcid">PMC6118596</pub-id></mixed-citation></ref><ref id="ame212486-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="ame212486-cit-0036"><string-name name-style="western"><surname>Cao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, et&#160;al. <article-title>PFKFB3&#8208;mediated endothelial glycolysis promotes pulmonary hypertension</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2019</year>;<volume>116</volume>:<fpage>13394</fpage>&#8208;<lpage>13403</lpage>.<pub-id pub-id-type="pmid">31213542</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1821401116</pub-id><pub-id pub-id-type="pmcid">PMC6613097</pub-id></mixed-citation></ref><ref id="ame212486-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="ame212486-cit-0037"><string-name name-style="western"><surname>Kovacs</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>W</given-names></string-name>, et&#160;al. <article-title>PFKFB3 in smooth muscle promotes vascular remodeling in pulmonary arterial Hypertension</article-title>. <source>Am J Respir Crit Care Med</source>. <year>2019</year>;<volume>200</volume>(<issue>5</issue>):<fpage>617</fpage>&#8208;<lpage>627</lpage>.<pub-id pub-id-type="pmid">30817168</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.201812-2290OC</pub-id><pub-id pub-id-type="pmcid">PMC6727156</pub-id></mixed-citation></ref><ref id="ame212486-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="ame212486-cit-0038"><string-name name-style="western"><surname>Xu</surname><given-names>JZ</given-names></string-name>, <string-name name-style="western"><surname>Conrey</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Frey</surname><given-names>I</given-names></string-name>, et&#160;al. <article-title>A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG&#8208;348) in sickle cell disease</article-title>. <source>Blood</source>. <year>2022</year>;<volume>140</volume>(<issue>19</issue>):<fpage>2053</fpage>&#8208;<lpage>2062</lpage>.<pub-id pub-id-type="pmid">35576529</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood.2022015403</pub-id><pub-id pub-id-type="pmcid">PMC9837441</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>